Liraglutide: Mechanism, Research & UK Safety Profile
Also known as: Victoza, Saxenda, NN2211
A first-generation once-daily GLP-1 receptor agonist developed by Novo Nordisk, MHRA-licensed as Victoza for type 2 diabetes and Saxenda for weight management, foundational to the incretin agonist research field.
Molecular formula
C₁₇₂H₂₆₅N₄₃O₅₁
Molecular weight
3751.2 Da
Half-life
Approximately 13 hours following subcutaneous injection, mediated by C-16 palmitic acid–albumin binding. This shorter half-life relative to semaglutide necessitates once-daily rather than once-weekly dosing, and is associated with greater plasma concentration fluctuation between doses.
Category
GLP-1/GIP Agonists
Overview
Liraglutide is a 97% sequence-homologous analogue of human glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk A/S. It was the first GLP-1 receptor agonist to achieve regulatory approval for weight management and served as the pharmacological proof-of-concept that chronic GLP-1 receptor agonism could produce clinically meaningful, sustained weight loss in humans. Its development history is foundational to understanding the entire class of incretin-based therapies that followed.
Liraglutide's structure differs from native GLP-1(7-37) primarily by substitution of arginine at position 26 with lysine, attachment of a C-16 palmitic acid chain via a glutamate-miniPEG spacer at this lysine, and the arginine at position 34 replaced with lysine. The C-16 fatty acid enables reversible albumin binding, extending the plasma half-life from the approximately 2-minute half-life of native GLP-1 to approximately 13 hours—sufficient for once-daily subcutaneous dosing with stable plasma concentrations throughout the 24-hour period.
In the United Kingdom, liraglutide is an MHRA-licensed prescription medicine in two formulations: Victoza (1.2 mg and 1.8 mg subcutaneous injection, once daily) for the management of type 2 diabetes mellitus; and Saxenda (3.0 mg subcutaneous injection, once daily) for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, in conjunction with dietary modification and increased physical activity. Both formulations are prescription-only medicines in the UK.
The clinical evidence base for liraglutide encompasses the SCALE programme (SCALE Obesity and Pre-diabetes, SCALE Diabetes, SCALE Maintenance, SCALE Sleep Apnoea) and the LEADER cardiovascular outcomes trial, the latter demonstrating a 13% relative reduction in MACE in type 2 diabetes with high cardiovascular risk—the first positive cardiovascular outcomes trial for a GLP-1 receptor agonist. As the predecessor to semaglutide, liraglutide's clinical dataset provides the historical benchmark against which later, higher-efficacy agents are contextualised by researchers in incretin pharmacology.
Discovery & Research History
Liraglutide's development at Novo Nordisk began in the 1990s as part of the company's pioneering programme to harness GLP-1's insulinotropic and glucoregulatory effects for diabetes treatment. The central challenge was overcoming native GLP-1's extremely short plasma half-life of approximately 1–2 minutes, resulting from rapid N-terminal cleavage by DPP-4 and renal clearance of the resulting fragments.
Novo Nordisk's research teams, drawing on earlier work with exendin-4 (a naturally DPP-4-resistant GLP-1 receptor agonist found in Gila monster venom), sought to engineer DPP-4 resistance and albumin binding directly into a human GLP-1 analogue. The fatty acid conjugation approach—proven effective for insulin detemir, another Novo Nordisk product—was adapted for peptide use. The attachment of a C-16 palmitic acid via a linker at position 26 achieved the necessary albumin-binding affinity without substantially disrupting GLP-1 receptor binding.
Preclinical studies in the late 1990s and early 2000s demonstrated that liraglutide (NN2211) maintained GLP-1 receptor agonism in animal models with substantially extended duration of action. Phase 1 clinical pharmacology studies confirmed the once-daily pharmacokinetic profile and acceptable tolerability in human volunteers. The LEAD (Liraglutide Effect and Action in Diabetes) Phase 3 programme (LEAD-1 through LEAD-6) was conducted in the mid-to-late 2000s, with results supporting regulatory submissions.
Liraglutide (Victoza) received European regulatory approval in 2009 and US FDA approval in 2010 for type 2 diabetes, representing the first once-daily GLP-1 receptor agonist to reach the market. The higher-dose Saxenda formulation for weight management received approval in the EU in 2015 following the SCALE programme, establishing GLP-1 receptor agonism as an obesity pharmacotherapy—a clinical category that had been essentially dormant since the withdrawal of rimonabant.
The LEADER cardiovascular outcomes trial, published in The New England Journal of Medicine in 2016, provided the first evidence of cardiovascular mortality reduction with any diabetes medication in a dedicated outcomes trial, marking liraglutide as a landmark compound in the history of metabolic medicine and setting the stage for the cardiovascular outcomes investigations of subsequent GLP-1 agents.
Mechanism of Action
Liraglutide shares the core GLP-1 receptor agonist mechanism with semaglutide and the GLP-1 component of tirzepatide, acting through the same receptor distributed across pancreatic, central, gastrointestinal, cardiovascular, and renal tissues:
Pancreatic Insulin Secretion Enhancement
Liraglutide binds to GLP-1 receptors on pancreatic beta cells with high affinity, activating adenylyl cyclase and raising intracellular cAMP. This potentiates glucose-stimulated insulin secretion through PKA and EPAC2 pathways. The response is glucose-dependent, attenuating at euglycaemia and providing an inherent safety margin against hypoglycaemia as monotherapy. This mechanism forms the basis of liraglutide's use in type 2 diabetes management.
Glucagon Suppression
GLP-1 receptor agonism on pancreatic alpha cells reduces glucagon secretion in a glucose-dependent manner, reducing hepatic glucose output from both glycogenolysis and gluconeogenesis pathways. This contributes to the overall HbA1c lowering that is not fully accounted for by the insulin-secretory effect alone.
Central Appetite and Satiety Regulation
GLP-1 receptors in the arcuate and paraventricular nuclei of the hypothalamus, and in the brainstem nucleus tractus solitarius, integrate signals from peripheral satiety hormones. Liraglutide crosses the blood-brain barrier at circumventricular organs lacking a tight barrier and directly activates these central circuits, reducing hunger ratings, increasing satiety, and reducing caloric consumption. Mechanistic studies quantify a reduction in voluntary energy intake of approximately 16–20% at the 3.0 mg Saxenda dose—somewhat less than the approximately 35% seen with semaglutide 2.4 mg, consistent with the lower weight-loss magnitude.
Gastric Emptying Delay
Liraglutide slows gastric emptying through vagal GLP-1 receptor-mediated pathways. This moderates the rate of carbohydrate and lipid absorption, reducing postprandial glucose and triglyceride excursions. As with all GLP-1 receptor agonists, this effect exhibits partial tachyphylaxis with chronic administration.
Cardiovascular Effects
LEADER trial mechanistic sub-studies suggest that liraglutide's cardiovascular benefits include: anti-inflammatory effects on vascular endothelium; improvements in endothelial function and arterial stiffness; reductions in blood pressure and heart rate; and potentially direct cardiomyocyte protective signalling. The CV benefit was most prominent in participants with established atherosclerotic cardiovascular disease, consistent with plaque-stabilising or ischaemic conditioning mechanisms.
Beta-Cell Preservation
Preclinical evidence and LEAD programme sub-studies suggest liraglutide may have beta-cell trophic effects, potentially preserving beta-cell mass and function over time through anti-apoptotic signalling. This mechanism is relevant to the concept of disease modification in type 2 diabetes, though definitive human evidence remains limited.
Researched Effects
- Mean body-weight reduction of approximately 8.0% at 56 weeks with liraglutide 3.0 mg in SCALE Obesity and Pre-diabetes, in adults with obesity without type 2 diabetes.
- HbA1c reductions of approximately 1.0–1.5 percentage points in LEAD trials in type 2 diabetes, with high rates of target attainment at below 7%.
- 13% relative reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) in the LEADER trial in adults with type 2 diabetes and high cardiovascular risk, representing a statistically significant superiority finding.
- Significant reductions in systolic blood pressure (approximately 3–5 mmHg), consistent with GLP-1 receptor-mediated natriuresis and vasodilatory mechanisms.
- Improvements in hepatic steatosis markers and exploratory NASH-relevant endpoints in obesity sub-studies, consistent with the class mechanism.
- Meaningful weight loss maintenance demonstrated in SCALE Maintenance, where liraglutide 3.0 mg preserved weight loss in participants who had achieved dietary-induced weight reduction.
- Reduction in progression from pre-diabetes to type 2 diabetes observed in SCALE Obesity and Pre-diabetes over 160-week follow-up, with liraglutide-treated participants showing 80% lower risk of progression.
- Improvements in obstructive sleep apnoea severity (AHI reduction) in SCALE Sleep Apnoea, with implications for research into the relationship between weight loss and upper airway physiology.
Theoretical Research Protocols
- Dosage range
- Saxenda (weight management): escalation from 0.6 mg/day to 1.2 mg, 1.8 mg, 2.4 mg, reaching 3.0 mg/day maintenance over 5 weeks; Victoza (diabetes): 0.6 mg/day initiation, 1.2 mg maintenance, 1.8 mg maximum
- Frequency
- Once daily subcutaneous injection; consistent timing each day recommended in trial protocols to maintain stable plasma concentrations
- Duration
- SCALE Obesity: 56 weeks primary endpoint, 160-week extension; LEADER: median 3.8 years; LEAD trials: 26–52 weeks
- Administration routes
- Subcutaneous injection via prefilled pen (Saxenda 3.0 mg; Victoza 1.2 mg and 1.8 mg) — once daily, any time of day independent of meals
Safety Profile
Common side effects (research)
- Nausea — the most frequently reported adverse event, occurring in approximately 32–40% of participants at 3.0 mg in SCALE trials; most prominent during dose escalation and generally self-limiting
- Diarrhoea — reported in approximately 17–21% of participants in SCALE trials at 3.0 mg
- Constipation — reported in approximately 19–24% of participants, a higher rate than seen with semaglutide in comparable populations
- Vomiting — reported in approximately 9–16% at 3.0 mg during escalation phases
- Headache and dizziness, particularly during dose-initiation phases
- Injection-site reactions including erythema, itching, and transient induration
- Increased heart rate — modest resting tachycardia of approximately 2–3 bpm, consistent with GLP-1 class effects
Rare risks
- Acute pancreatitis — regulatory class risk; incidence in LEADER and SCALE populations was low with no statistically significant difference from placebo
- Cholelithiasis — elevated risk associated with rapid weight loss; observed at low but measurable frequencies across SCALE programmes
- Thyroid C-cell effects — rodent carcinogenicity class warning; no elevated thyroid cancer rates observed in human LEADER or SCALE populations
- Hypoglycaemia — low risk as monotherapy; significantly elevated when co-administered with insulin or sulphonylureas in type 2 diabetes management
- Acute kidney injury — predominantly through dehydration secondary to gastrointestinal adverse events; monitor hydration in susceptible participants
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2
- Prior serious hypersensitivity to liraglutide or any formulation component
- Pregnancy and breastfeeding
- Active or significant history of pancreatitis
- Severe hepatic impairment (limited pharmacokinetic data)
UK Regulatory Status
United Kingdom (MHRA): Liraglutide is an MHRA-licensed prescription-only medicine in two formulations: Victoza (1.2 mg and 1.8 mg) for type 2 diabetes management and Saxenda (3.0 mg) for chronic weight management. Both may only be dispensed by or under the direction of a licensed UK prescriber. Victoza's type 2 diabetes indication is established; Saxenda's weight-management indication requires meeting BMI criteria. Saxenda has faced NHS formulary restrictions in some health systems, and patients may need to access it through specialist or private pathways.
European Union (EMA): Liraglutide (Victoza and Saxenda) holds EMA marketing authorisation for its respective indications across all EU member states. It is a prescription-only medicine under the centralised authorisation procedure.
Notes: Liraglutide is prohibited by WADA in competitive sport. As the predecessor compound to semaglutide in Novo Nordisk's GLP-1 portfolio, its clinical evidence base—particularly LEADER's cardiovascular mortality data—is historically significant and frequently referenced in mechanistic research exploring incretin cardiovascular protection. Its shorter half-life and daily injection requirement have led most new clinical research programmes to favour once-weekly semaglutide or tirzepatide.
Related research resources
Key Research Studies
SCALE Obesity and Pre-diabetes: Liraglutide 3.0 mg in Nondiabetic Overweight or Obese Adults
A 56-week primary, 160-week extended randomised, double-blind, placebo-controlled trial enrolling 3,731 adults with obesity or overweight with comorbidities. Liraglutide 3.0 mg produced a mean weight reduction of 8.0% versus 2.6% with placebo at 56 weeks. Over 160 weeks, liraglutide-treated participants showed an 80% lower risk of progressing from pre-diabetes to type 2 diabetes, a finding with long-term public health implications.
Read sourceLEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
A randomised, double-blind, placebo-controlled cardiovascular outcomes trial in 9,340 adults with type 2 diabetes and high cardiovascular risk. Over a median 3.8 years, liraglutide 1.8 mg daily reduced the primary MACE composite by 13% (HR 0.87, 95% CI 0.78–0.97). Cardiovascular death was significantly reduced (HR 0.78). This was the first positive cardiovascular outcomes trial for a GLP-1 receptor agonist, establishing the CV protective framework for the entire class.
Read sourceSCALE Sleep Apnoea: Effect of Liraglutide on Obstructive Sleep Apnoea
A 32-week randomised trial in 359 adults with obese-related obstructive sleep apnoea not using CPAP therapy. Liraglutide 3.0 mg produced a mean reduction in apnoea-hypopnoea index (AHI) of 12.2 events/hour versus 6.1 events/hour with placebo. Weight loss of 5.7% versus 1.6% was observed. The results are frequently cited in research exploring the mechanistic relationship between adiposity and upper airway physiology.
Read sourceLEAD-6: Liraglutide versus Exenatide Once Weekly in Type 2 Diabetes
A 26-week open-label randomised trial directly comparing liraglutide 1.8 mg daily with exenatide 2 mg weekly in 464 adults with type 2 diabetes. Liraglutide produced significantly greater HbA1c reduction (−1.12% vs −0.79%) and body weight reduction (−3.24 kg vs −2.87 kg), alongside a more favourable gastrointestinal tolerability profile. This head-to-head comparison was instrumental in establishing liraglutide's competitive position within the GLP-1 receptor agonist class.
Read sourceFrequently Asked Questions
What is liraglutide and what is it used for?
Liraglutide is a synthetic analogue of the gut hormone GLP-1, modified with a C-16 fatty acid chain to extend its plasma half-life to approximately 13 hours for once-daily dosing. In the UK it is licensed as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. It was the first GLP-1 receptor agonist approved for obesity pharmacotherapy, establishing the mechanistic proof-of-concept for this entire therapeutic class.
How does liraglutide compare to semaglutide for weight loss?
Semaglutide 2.4 mg weekly (STEP 1: −14.9%) produces approximately twice the weight loss of liraglutide 3.0 mg daily (SCALE: −8.0%) in comparable non-diabetic obese populations. This difference is attributable to semaglutide's greater central appetite-suppressing potency, its longer half-life producing more stable receptor occupation, and its higher dose relative to the GLP-1 receptor agonism benchmark. Daily injection versus once-weekly administration is also a practical differentiator in clinical and research contexts.
Is liraglutide available on the NHS in the UK?
Victoza (liraglutide for type 2 diabetes) is available on NHS prescription within approved prescribing guidelines. Saxenda (liraglutide for weight management) has had restricted NHS availability, with access through specialist obesity services and subject to local formulary decisions. NICE guidance TA664 covers liraglutide for weight management with specific BMI and comorbidity criteria. Private prescribing is available through appropriate clinicians.
Why does liraglutide require daily injection while semaglutide only needs weekly?
The difference stems from their fatty acid conjugation strategies: liraglutide uses a C-16 palmitic acid chain, producing albumin binding that extends half-life to approximately 13 hours—sufficient for once-daily dosing. Semaglutide uses a C-18 fatty diacid chain with a longer hydrophilic spacer, producing tighter albumin binding and a half-life of approximately 7 days. Novo Nordisk specifically engineered semaglutide's linker chemistry to achieve this further extension after liraglutide established the feasibility of the approach.
What were the key cardiovascular findings from the LEADER trial?
The LEADER trial enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk, followed for a median 3.8 years. Liraglutide 1.8 mg daily reduced the primary MACE composite (cardiovascular death, non-fatal MI, non-fatal stroke) by 13% relative to placebo (HR 0.87), driven principally by a significant 22% reduction in cardiovascular death. This was the first positive cardiovascular outcomes trial for any GLP-1 receptor agonist and established the cardiovascular protective framework that subsequent SELECT and SUSTAIN-6 trials built upon.
Is liraglutide still clinically relevant given newer once-weekly agents?
Yes. While semaglutide and tirzepatide have largely superseded liraglutide in new clinical prescribing for weight management due to greater efficacy and more convenient weekly dosing, liraglutide retains clinical relevance for patients with specific tolerability profiles, in type 2 diabetes management, and as a comparator in ongoing mechanistic research. Its comprehensive clinical dataset—SCALE, LEADER, LEAD 1–6—remains a foundational reference for incretin biology researchers.